LATP

LATP:

Two leading products (LTP-03, and LTP-0401) are in early pre-clinical stage. The efficacy and toxicity were confirmed in rodent studies. IND-enabling studies of LTP-03 has been in progress

LTP-03
  • Balanced GLP-1R and GCGR activation, and enhanced GIPR activation
  • All naturalamino acid and no chemical modifacations renders low immunogenicity
  • MininalCNS exposure, mild effect on food intake
  • Half-life similar to Semaglutide in mice; Co-administration with Sitagliptin (a DPPIV inhibitor) further extended the half-life.
  • Mimic physiological properties of native peptides: no sustained activation of related receptors
  • Similar physiochemical and pharmacological profiles, and CMC to Dulaglutide
  • Potentially armed with additional metabolic hormones
  • Reduced GCGR activation with enhanced GIPR activation
  • Similar to native sequence and containing only natural amino acids, thus decreasing any immunogenicity risk
  • Monovalent analogs mimic physiological properties of native peptides, no sustained activation of related receptors
  • Minimal CNS exposure, mild effect on food intake
  •  Prolonged half-life
  • Similar physiochemical and pharmacological profiles, and CMC to Dulaglutide
Scroll to Top